Status:
COMPLETED
Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis
Lead Sponsor:
Swedish Orphan Biovitrum
Collaborating Sponsors:
M.D. Anderson Cancer Center
Conditions:
Hemophagocytic Lymphohistiocytosis
Eligibility:
All Genders
Brief Summary
This observational study is designed to determine the levels of pro-inflammatory markers in patients diagnosed with M-HLH, and to assess whether the cytokine profiles bear an IFNγ signature.
Detailed Description
This is a observational study designed to determine the levels of inflammatory markers in patients diagnosed with M-HLH and to assess the relationship between the biomarkers and disease activity in th...
Eligibility Criteria
Inclusion
- Patients diagnosed with HLH in the context of a malignancy. The diagnosis of M-HLH will be established by the treating physician.
- The patient or patient's legal representative (in case the patient is \< 18 years old) must have consented to the use of their clinical data for research purposes at the site.
- For the control group, patients with a diagnosis of hematological malignancy and never diagnosed with HLH or no suspicion of HLH
Exclusion
- N/A
Key Trial Info
Start Date :
October 13 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 29 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03259230
Start Date
October 13 2016
End Date
January 29 2020
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030